News about DMD Partners Canada
Apr. 2022
Vimega NMN 12000 certified by NPN Canada (certification number: 80117965)
Apr. 2022
Vimega NMN 9600 certified by NPN Canada (certification number: 80117966)
Feb. 2022
Vimega Brand is available for sale on JD.com
Nov. 2021
DMD has authorized D1M Asia Limited, one of the leading branded e-commerce service providers in China, to be the operational partner of Vimega brand’s cross-border e-commerce services such as Tmall International and Jingdong International, providing omnichannel CRM.
Aug. 2021
Vimega and Dr.Mighty Brand are available for sale on SeaBreeze of United States.
Jul 7, 2021
The Chairman of DMD Weiping Feng and its UltraSpec Dr. Zhan Ye, Dr. Jingwei Luo and Dr. Dandan Huang, held a high-level seminar with BOCI’s Director and General Manager Shanxue Liu, Dr. Jianming Xin from the Investment Department and Dr. Chenghua Hu from the Investment Banking Department of the Medical and Pharmaceutical Group. BOCI plans to raise USD150 million to focus on the commercial application of the AI AI medical and big health database owned by UltraSpec, and to integrate AI throughout the whole process of new drug development, including target discovery platform, small molecule compound design and generation platform algorithm, and clinical trial result generation platform, to build UltraSpec into a world-leading medical and big Health Lab.
Jun. 2021
Hero Essence Dr. Mighty Formula approved by US FDA (Certificate No. HVWG-JMJ3)
Jun. 2021
Dr. Jingwei Luo, one of the directors of DMD’s Ultraspec Lab, was invited to be a guest of Sino TV’s Chinese TV Parlour in Los Angeles to decipher the truth of human aging and introduce the story behind Vimega NMN products to the North American audience.
Jun. 2021
Vimega Brand is available for sale on YunJi Mall.
Jun. 2021
Vimega NMN 15000 approved by US FDA (Certificate No. C5FU-VHC3)
Jun. 2021
Fount’y’s entry into ‘Gialees Choice’ was covered by mainstream North American news media such as PR Newswire, Yahoo News, Fox News, and Canada Insider, etc.
Apr. 2021
Vimega NMN 9600 and 12000 are FDA approved (certificate number: FB7U-2MVQ)
Mar. 2021
Fount’y NMN 12000 approved by US FDA (certificate number: 6C23-UM4H)
Jan. 2021
DMD Partners Canada Ltd. has been certified by the U.S. FDA as an approved company (Certificate No. 14243218528)
2020
DMD’s R&D Lab (UltraSpec Lab) has successfully developed a series of NMN dietary supplements with targeted effects using the most advanced AI (Artificial Intelligence) pharmaceutical formulation technology and the lab’s own health database. The NMN series of dietary supplements from DMD use high-purity NMN (β-nicotinamide mononucleotide) obtained by the most advanced fourth-generation directed evolutionary bioenzyme fermentation method as the raw material, combined with the laboratory’s exclusive formula, which has obvious and long-lasting effects.
2020
DMD Product Development Center (Ultraspec Lab) has successfully reverse-translated in-house designed protein sequences into mRNA drugs, which can solve the common problem of poor cellular permeability of protein drugs.
2020
DMD R&D Center (Ultraspec Lab) applied AI (Artificial intelligence) to Pharmaceutical development, and developed four innovative drug formulations for adjuvant cancer treatment, local anti-inflammatory, chronic pain, and tranquilization & antidepressant with industrial cannabidiol (CBD) as the main raw material using self-developed AI cellular-level human organ metabolism simulator, which was awarded by BOC International, Hong Kong Continued interest.